SeaPRwire
Read More

Potential New Therapeutic Approach for Pancreatic Cancer is proposed at 2022 Keystone Meeting: Blocking Obesity or Fatty Acid Oxidation

pandora
2 minutes

Seoul, Korea, September 08, 2022 – (SEAPRWire) – In “the immunometabolism at the crossroads of obesity and cancer, Keystone Symposia (Sept. 5-9, 2022, Keystone, Co, USA)”, Dr. Soo-Youl Kim, Principal Scientist of the National Cancer Center of South Korea, showed that cancer obtains energy absolutely by burning fatty acids from blood as well as that obesity causes cancer to grow explosively by burning fat. Therefore, calorie balanced carbohydrate diet reduced tumor growth 1/5 to compare to high fat diet in mouse cancer model. It is proposed as ‘Kim effect’ in the latest Seminars in Cancer Biology journal that cancer energy metabolism absolutely depends on fatty acids (https://doi.org/10.1016/j.semcancer.2022.07.005). This announcement is expected to make great strides in cancer metabolism treatment and immunotherapy and foreshadows the emergence of new anticancer drugs that control obesity and fat catabolism. Dr. Kim announced that anti-cancer drug targeting fatty acid oxidation will be in clinical trial in South Korea. Know more, please contact Dr. Soo-Youl Kim, Principal Scientist of National Cancer Center, Korea. E: tgase@ncc.re.kr W: www.ncc.re.kr The article is provided by a th...

ACN Newswire
Read More

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG and Apollo REVISE, New Endoscopic Systems for Patients with Obesity

indie
7 minutes

AUSTIN, TX, Jul 13, 2022 - (ACN Newswire via SEAPRWire.com) - Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today the marketing authorization of the Apollo ESG(TM), Apollo ESG Sx(TM), Apollo REVISE(TM) and Apollo REVISE Sx(TM) Systems through the U.S. Food and Drug Administration's (FDA) De Novo Classification process, a rigorous pre-market review pathway for low-to moderate-risk devices without a predicate. These are the first and only devices authorized by the FDA for endoscopic sleeve gastroplasty (ESG) and endoscopic bariatric revision.ESG is an incisionless procedure that utilizes an endoscopic suturing system to reduce the volume of a person's stomach and delay emptying of the stomach, resulting in clinically meaningful, durable weight loss. In a randomized controlled trial, the ESG procedure demonstrated safety and effectiveness with durability out to two years.[1] The results from this trial add to a larger body of evidence reporting outcomes in over 10,000 patients receiving ESG. ESG can be performed as a same-day procedure without incisions or scars, and pat...